CHICAGO -- An investigational, oral small-molecule GLP-1 receptor agonist improved glycated hemoglobin levels in adults with ...

Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of ...

With semaglutide and tirzepatide dosed once weekly, their estimated average yearly costs in the U.S. are $14,080 and $8,126, ...

At HLTH Europe 2025, experts warned that stigma, cost barriers, and lack of support are hindering the wider use of GLP-1s in ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

GLP-1 drugs like Ozempic help with weight loss, but how do they stack up against bariatric surgery? A new study breaks it ...

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, ...

Patients on GLP-1 medications lost about half as much weight as participants did in clinical trials, NYU researchers found.

Bariatric surgery is associated with a significantly greater long-term weight loss than treatment with GLP-1 receptor ...

Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.

Ohio to end GLP-1 drug coverage for most state workers without diabetes, citing soaring Medicaid costs and rising demand for ...

GLP-1 drugs such as Wegovy and Zepbound are growing increasingly prominent. But some food ingredients can also cause the body ...